Generate Biomedicines
GENB
13.57
-0.23
-1.67%
Generate Biomedicines
US · GENB
#2875 by market cap
Listed 2026
13.57
-0.23
-1.67%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 08:20
Pre-market
13.57
0.00%
After-hours
13.57
0.00%
Overnight
13.71
+1.03%
- Market cap
- 1.74B
- P/E (TTM)i
- -6.48
- P/Bi
- 3.82
- EPSi
- -1.96
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on GENB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.47, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +55.89% YoY
Margins
- Operating margin
- -737.04%
- Net margin
- -782.38%
Key ratios & quality
- Altman Z-Scorei
- -3.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Gross profit | -- | -- |
| Selling & admin expenses | 42.09M | 42.26M |
| Research & development | 175.31M | 224.70M |
| Operating profit | -196.94M | -235.07M |
| Pretax profit | -181.17M | -222.80M |
| Tax | 212.00K | 163.00K |
| Net profit | -181.38M | -222.97M |
| Basic EPS | -2 | -2 |
| Diluted EPS | -2.09 | -2.18 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | 8.82M | 10.13M | 7.22M | 6.31M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 10.15M | 10.55M | 13.52M | 13.60M |
| Research & development | 46.83M | 59.74M | 57.81M | 64.33M |
| Operating profit | -48.15M | -60.15M | -64.11M | -71.61M |
| Pretax profit | -44.26M | -56.70M | -61.69M | -67.20M |
| Tax | 56.00K | 44.00K | 28.00K | 53.00K |
| Net profit | -44.31M | -56.74M | -61.71M | -67.26M |
| Basic EPS | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.52 | -0.63 | -1.07 | -0.52 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 407.49M | 234.37M |
| Cash & ST investments | 393.63M | 221.50M |
| Inventory | -- | -- |
| Total assets | 518.26M | 330.18M |
| Total current liabilities | 86.63M | 82.20M |
| Short-term debt | 16.72M | 15.01M |
| Long-term debt | -- | -- |
| Total liabilities | 953,349,000.00 | 953,379,000.00 |
| Total equity | -435.09M | -623.20M |
| Retained earnings | -473.14M | -676.29M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 535.39M | 470.25M |
| Cash & ST investments | -- | -- | 516.64M | 457.42M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 625.74M | 561.69M |
| Total current liabilities | -- | -- | 58.39M | 56.64M |
| Short-term debt | -- | -- | 14.26M | 13.62M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 110,936,000.00 | 105,645,000.00 |
| Total equity | -- | -- | 514.80M | 456.05M |
| Retained earnings | -- | -- | -737.74M | -804.99M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -117.75M | -200.62M |
| Depreciation & amortization | 15.35M | 13.18M |
| Free cash flow | -121.20M | -204.13M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 181.83M | 126.04M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -53.18M | -48.75M | -80.39M | -57.94M |
| Depreciation & amortization | 3.41M | 3.32M | 3.27M | 3.22M |
| Free cash flow | -53.93M | -48.91M | -84.17M | -58.88M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 369.29M | 0 |
| Ending cash balance | 224.75M | 158.66M | 164.61M | 139.39M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -41.25 | -58.82 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -875.18 | -695.03 |
| FCF / sales %i | -- | -- |
| Current ratioi | 4.70 | 2.85 |
| Quick ratioi | 4.55 | 2.69 |
| Debt / assetsi | 14.85 | 20.75 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -84.54 | -195.13 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -51.56 | -58.91 |
| ROA %i | -- | -- | -42.42 | -47.83 |
| ROIC %i | -- | -- | -46.91 | -53.23 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -789.73 | -943.76 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 9.17 | 8.30 |
| Quick ratioi | -- | -- | 8.85 | 8.08 |
| Debt / assetsi | -- | -- | 10.48 | 11.15 |
| LT debt / equityi | -- | -- | 9.97 | 10.75 |
| Interest coveragei | -- | -- | -251.87 | -313.20 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Field of generative biology by using machine learning for drug discovery and development through the100.00%
Quote time 2026-10-08 08:20:40 · For reference only, not investment advice and not tailored to your situation.